| Literature DB >> 33805488 |
Kristen Renee McSweeney1, Laura Kate Gadanec1, Tawar Qaradakhi1, Benazir Ashiana Ali1, Anthony Zulli1, Vasso Apostolopoulos1.
Abstract
Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which has been linked to cellular uptake and efflux, apoptosis, vascular injury, oxidative and endoplasmic reticulum stress, and inflammation. Despite research efforts, pharmaceutical interventions, and clinical trials spanning over several decades, a consistent and stable pharmacological treatment option to reduce AKI in patients receiving cisplatin remains unavailable. This has been predominately linked to the incomplete understanding of CIAKI pathophysiology and molecular mechanisms involved. Herein, we detail the extensively known pathophysiology of cisplatin-induced nephrotoxicity that manifests and the variety of pharmacological and genetic alteration studies that target them.Entities:
Keywords: AKI; acute kidney injury; cisplatin; cisplatin-induced acute kidney injury; nephrotoxicity
Year: 2021 PMID: 33805488 PMCID: PMC8036620 DOI: 10.3390/cancers13071572
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639